Cargando…

Combination of a Sindbis-SARS-CoV-2 spike vaccine and αOX40 antibody elicits protective immunity against SARS-CoV-2 induced disease and potentiates long-term SARS-CoV-2-specific humoral and T-cell immunity.

The COVID-19 pandemic caused by the coronavirus SARS-CoV-2 is a major global public threat. Currently, a worldwide effort has been mounted to generate billions of effective SARS-CoV-2 vaccine doses to immunize the world’s population at record speeds. However, there is still demand for alternative ef...

Descripción completa

Detalles Bibliográficos
Autores principales: Scaglione, Antonella, Opp, Silvana, Hurtado, Alicia, Lin, Ziyan, Pampeno, Christine, Noval, Maria G, Thannickal, Sara A., Stapleford, Kenneth A., Meruelo, Daniel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cold Spring Harbor Laboratory 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8168399/
https://www.ncbi.nlm.nih.gov/pubmed/34075383
http://dx.doi.org/10.1101/2021.05.28.446009
_version_ 1783701874119016448
author Scaglione, Antonella
Opp, Silvana
Hurtado, Alicia
Lin, Ziyan
Pampeno, Christine
Noval, Maria G
Thannickal, Sara A.
Stapleford, Kenneth A.
Meruelo, Daniel
author_facet Scaglione, Antonella
Opp, Silvana
Hurtado, Alicia
Lin, Ziyan
Pampeno, Christine
Noval, Maria G
Thannickal, Sara A.
Stapleford, Kenneth A.
Meruelo, Daniel
author_sort Scaglione, Antonella
collection PubMed
description The COVID-19 pandemic caused by the coronavirus SARS-CoV-2 is a major global public threat. Currently, a worldwide effort has been mounted to generate billions of effective SARS-CoV-2 vaccine doses to immunize the world’s population at record speeds. However, there is still demand for alternative effective vaccines that rapidly confer long-term protection and rely upon cost-effective, easily scaled-up manufacturing. Here, we present a Sindbis alphavirus vector (SV), transiently expressing the SARS-CoV-2 spike protein (SV.Spike), combined with the OX40 immunostimulatory antibody (αOX40) as a novel, highly effective vaccine approach. We show that SV.Spike plus αOX40 elicits long-lasting neutralizing antibodies and a vigorous T-cell response in mice. Protein binding, immunohistochemical and cellular infection assays all show that vaccinated mice sera inhibits spike functions. Immunophenotyping, RNA Seq transcriptome profiles and metabolic analysis indicate a reprogramming of T-cells in vaccinated mice. Activated T-cells were found to mobilize to lung tissue. Most importantly, SV.Spike plus αOX40 provided robust immune protection against infection with authentic coronavirus in transgenic mice expressing the human ACE2 receptor (hACE2-Tg). Finally, our immunization strategy induced strong effector memory response, potentiating protective immunity against re-exposure to SARS-CoV-2 spike protein. Our results show the potential of a new Sindbis virus-based vaccine platform to counteract waning immune response that can be used as a new candidate to combat SARS-CoV-2. Given the strong T-cell responses elicited, our vaccine is likely to be effective against variants that are proving challenging, as well as, serve as a platform to develop a broader spectrum pancoronavirus vaccine. Similarly, the vaccine approach is likely to be applicable to other pathogens.
format Online
Article
Text
id pubmed-8168399
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Cold Spring Harbor Laboratory
record_format MEDLINE/PubMed
spelling pubmed-81683992021-06-02 Combination of a Sindbis-SARS-CoV-2 spike vaccine and αOX40 antibody elicits protective immunity against SARS-CoV-2 induced disease and potentiates long-term SARS-CoV-2-specific humoral and T-cell immunity. Scaglione, Antonella Opp, Silvana Hurtado, Alicia Lin, Ziyan Pampeno, Christine Noval, Maria G Thannickal, Sara A. Stapleford, Kenneth A. Meruelo, Daniel bioRxiv Article The COVID-19 pandemic caused by the coronavirus SARS-CoV-2 is a major global public threat. Currently, a worldwide effort has been mounted to generate billions of effective SARS-CoV-2 vaccine doses to immunize the world’s population at record speeds. However, there is still demand for alternative effective vaccines that rapidly confer long-term protection and rely upon cost-effective, easily scaled-up manufacturing. Here, we present a Sindbis alphavirus vector (SV), transiently expressing the SARS-CoV-2 spike protein (SV.Spike), combined with the OX40 immunostimulatory antibody (αOX40) as a novel, highly effective vaccine approach. We show that SV.Spike plus αOX40 elicits long-lasting neutralizing antibodies and a vigorous T-cell response in mice. Protein binding, immunohistochemical and cellular infection assays all show that vaccinated mice sera inhibits spike functions. Immunophenotyping, RNA Seq transcriptome profiles and metabolic analysis indicate a reprogramming of T-cells in vaccinated mice. Activated T-cells were found to mobilize to lung tissue. Most importantly, SV.Spike plus αOX40 provided robust immune protection against infection with authentic coronavirus in transgenic mice expressing the human ACE2 receptor (hACE2-Tg). Finally, our immunization strategy induced strong effector memory response, potentiating protective immunity against re-exposure to SARS-CoV-2 spike protein. Our results show the potential of a new Sindbis virus-based vaccine platform to counteract waning immune response that can be used as a new candidate to combat SARS-CoV-2. Given the strong T-cell responses elicited, our vaccine is likely to be effective against variants that are proving challenging, as well as, serve as a platform to develop a broader spectrum pancoronavirus vaccine. Similarly, the vaccine approach is likely to be applicable to other pathogens. Cold Spring Harbor Laboratory 2021-06-02 /pmc/articles/PMC8168399/ /pubmed/34075383 http://dx.doi.org/10.1101/2021.05.28.446009 Text en https://creativecommons.org/licenses/by-nc-nd/4.0/This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License (https://creativecommons.org/licenses/by-nc-nd/4.0/) , which allows reusers to copy and distribute the material in any medium or format in unadapted form only, for noncommercial purposes only, and only so long as attribution is given to the creator.
spellingShingle Article
Scaglione, Antonella
Opp, Silvana
Hurtado, Alicia
Lin, Ziyan
Pampeno, Christine
Noval, Maria G
Thannickal, Sara A.
Stapleford, Kenneth A.
Meruelo, Daniel
Combination of a Sindbis-SARS-CoV-2 spike vaccine and αOX40 antibody elicits protective immunity against SARS-CoV-2 induced disease and potentiates long-term SARS-CoV-2-specific humoral and T-cell immunity.
title Combination of a Sindbis-SARS-CoV-2 spike vaccine and αOX40 antibody elicits protective immunity against SARS-CoV-2 induced disease and potentiates long-term SARS-CoV-2-specific humoral and T-cell immunity.
title_full Combination of a Sindbis-SARS-CoV-2 spike vaccine and αOX40 antibody elicits protective immunity against SARS-CoV-2 induced disease and potentiates long-term SARS-CoV-2-specific humoral and T-cell immunity.
title_fullStr Combination of a Sindbis-SARS-CoV-2 spike vaccine and αOX40 antibody elicits protective immunity against SARS-CoV-2 induced disease and potentiates long-term SARS-CoV-2-specific humoral and T-cell immunity.
title_full_unstemmed Combination of a Sindbis-SARS-CoV-2 spike vaccine and αOX40 antibody elicits protective immunity against SARS-CoV-2 induced disease and potentiates long-term SARS-CoV-2-specific humoral and T-cell immunity.
title_short Combination of a Sindbis-SARS-CoV-2 spike vaccine and αOX40 antibody elicits protective immunity against SARS-CoV-2 induced disease and potentiates long-term SARS-CoV-2-specific humoral and T-cell immunity.
title_sort combination of a sindbis-sars-cov-2 spike vaccine and αox40 antibody elicits protective immunity against sars-cov-2 induced disease and potentiates long-term sars-cov-2-specific humoral and t-cell immunity.
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8168399/
https://www.ncbi.nlm.nih.gov/pubmed/34075383
http://dx.doi.org/10.1101/2021.05.28.446009
work_keys_str_mv AT scaglioneantonella combinationofasindbissarscov2spikevaccineandaox40antibodyelicitsprotectiveimmunityagainstsarscov2induceddiseaseandpotentiateslongtermsarscov2specifichumoralandtcellimmunity
AT oppsilvana combinationofasindbissarscov2spikevaccineandaox40antibodyelicitsprotectiveimmunityagainstsarscov2induceddiseaseandpotentiateslongtermsarscov2specifichumoralandtcellimmunity
AT hurtadoalicia combinationofasindbissarscov2spikevaccineandaox40antibodyelicitsprotectiveimmunityagainstsarscov2induceddiseaseandpotentiateslongtermsarscov2specifichumoralandtcellimmunity
AT linziyan combinationofasindbissarscov2spikevaccineandaox40antibodyelicitsprotectiveimmunityagainstsarscov2induceddiseaseandpotentiateslongtermsarscov2specifichumoralandtcellimmunity
AT pampenochristine combinationofasindbissarscov2spikevaccineandaox40antibodyelicitsprotectiveimmunityagainstsarscov2induceddiseaseandpotentiateslongtermsarscov2specifichumoralandtcellimmunity
AT novalmariag combinationofasindbissarscov2spikevaccineandaox40antibodyelicitsprotectiveimmunityagainstsarscov2induceddiseaseandpotentiateslongtermsarscov2specifichumoralandtcellimmunity
AT thannickalsaraa combinationofasindbissarscov2spikevaccineandaox40antibodyelicitsprotectiveimmunityagainstsarscov2induceddiseaseandpotentiateslongtermsarscov2specifichumoralandtcellimmunity
AT staplefordkennetha combinationofasindbissarscov2spikevaccineandaox40antibodyelicitsprotectiveimmunityagainstsarscov2induceddiseaseandpotentiateslongtermsarscov2specifichumoralandtcellimmunity
AT meruelodaniel combinationofasindbissarscov2spikevaccineandaox40antibodyelicitsprotectiveimmunityagainstsarscov2induceddiseaseandpotentiateslongtermsarscov2specifichumoralandtcellimmunity